Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To conduct a systematic literature review of real-world evidence on the burden of tyrosine kinase inhibitor (TKI) failure in Chinese patients with chronic myeloid leukemia (CML). Methods: We identified 155 references in Chinese- and English-language journals from 2001 to 2021. Results: The age-adjusted mortality rate in Chinese CML patients was decreasing. Imatinib treatment had a higher annual treatment failure risk than nilotinib (0.199 vs 0.041). Patients with TKI treatment failure tended to be young (median: 38.6 years), have progressive disease (44.3%) and harbor BCR-ABL1 mutations (51.6%). The disease burden of TKI treatment failure included reduced health outcomes and increased health resource utilization and costs. Conclusion: CML relapse cases could continuously rise in China due to increasing TKI treatment failure over extended survival.
Supplementary Material
File (supplementary materials.docx)
- Download
- 16.04 KB
References
Papers of special note have been highlighted as: • of interest
1.
Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 286(8), 895–898 (2001).
2.
Druker BJ, Lydon NB. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105(1), 3–7 (2000).
3.
Hochhaus A, Larson RA, Guilhot F et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376(10), 917–927 (2017).
4.
Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin. Lymphoma Myeloma Leuk. 13(5), 515–529 (2013).
5.
Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Zhonghua Xue Ye Xue Za Zhi. 41(5), 353–364 (2020).
6.
Huang XJ. Hematopoietic stem cell transplantation in China: current status and prospects. Am. J. Blood Res. 1(1), 90–97 (2011).
7.
Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 25, 7–22 (2011).
8.
Lange T, Ernst T, Gruber FX et al. The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 98(5), 714–717 (2013).
9.
Osman AE, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Reviews 49, 100825 (2021).
10.
Wells GA, Shea B, O’Connell D et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (2011). www.ohri.ca/programs/clinical_epidemiology/oxford.asp
11.
Lin Q, Mao L, Shao L et al. Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Front. Oncol. 10, 580759 (2020).
12.
Bao PP, Wu CX, Zhang ML et al. Analysis of the characteristics and trends of the main subtypes of leukemia in Shanghai. J. Diagn. Concepts Pract. 16, 484–491 (2017).
13.
Linet MS, Gilbert ES, Dores GM et al. A retrospective cohort study of cause-specific mortality and incidence of hematopoietic malignancies in Chinese benzene-exposed workers. Int. J. Cancer 137, 2184–2197 (2015).
14.
Hua JJ, Xu ZK, Du JK, Han JH, Jia DD, Liang H. Analysis on the incidence of leukemia among workers in Shajing in Shenzhen. Chin. Prev. Med. 15, 260–263 (2014).
15.
Yu L, Qin YQ, Lai YY, Shi HX, Huang XJ, Jiang Q. Severe hematological adverse reactions during the period of taking tyrosine kinase inhibitors in patients with chronic myelogenous leukemia and their effects on treatment response. Chin. J. Hematol. 40(4), 281–287 (2019).
16.
Huang J, Wang L, Chen L et al. Changing treatment may affect the predictive ability of European treatment outcome study scoring for the prognosis of patients with chronic myeloid leukemia. Turk. J. Hematol. 34, 10–15 (2017).
17.
Zhang JJ, Yang LJ, Zhu Y et al. The efficacy and safety of imatinib or nilotinib in the first-line treatment of elderly patients with chronic myeloid leukemia in the chronic phase. J. Nanjing Med. Univ. (Nat. Sci.) 8, 1197–1201 (2019).
18.
Yin H, Chen Y, Chen L et al. Real-world evidence of molecular response to tyrosine kinase inhibitors from China supports European LeukemiaNet 2013 recommendations for the management of chronic myeloid leukaemia. Hemasphere 2, 875–876 (2018).
19.
Zhou M, Qiu HY, He GS et al. Multivariate analysis of drug resistance during the treatment of chronic myelogenous leukemia with imatinib. Chin. J. Hematol. 34(5), 395–398 (2013).
20.
Zhao HF, Zhang YL, Zu YL et al. Clinical observation of the effect of clonal chromosomal abnormalities in Philadelphia chromosome-negative cells on the curative effect of chronic myeloid leukemia. Chin. J. Intern. Med. 803, 4–7 (2019).
21.
Wang J, Gao SK, Li Z, Li MJ, Zhang LL, Song YP. Adverse hematological reactions in 435 patients with chronic myeloid leukemia after treatment with imatinib mesylate. J. Leuk. Lymphoma 12, 479–482 (2015).
22.
Chen J. The clinical dose and efficacy of imatinib in the treatment of chronic myeloid leukemia. World Clin. Med. 11, 87–88 (2017).
23.
Zhang CJ, Zheng XL, Zheng DD, Xia WL, Su XL. Comparative analysis of the prognostic system and factors of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Chin. Youjiang Med. J. 48(5), 339–344 (2020).
24.
Huang J, Zhao XL. Comparison of three prognostic scoring systems in evaluating the prognosis of chronic myeloid leukemia. J. Central South Univ. (Med. Sci.) 41(08), 809–814 (2016).
25.
Wang PP, Zhang PP, Zhang J, Xi YM. The estimated value of different scoring systems for the clinical efficacy of newly diagnosed patients with chronic myeloid leukemia. J. Exp. Hematol. 27(03), 723–728 (2019).
26.
Yang AL, Liu X, Wang XB et al. Efficacy of the first and second generation TKIs in the treatment of chronic myeloid leukemia. J. Med. Inf. 32(23), 78–81 (2019).
27.
Huang Q, Liu H, Li Y, Zhang XY, Wang XM. Early effect of domestic imatinib mesylate in the treatment of chronic myelogenous leukemia patients. Cancer Res. Clin. 28(12), 811–814 (2016).
28.
Zhang JZ, Bao Y, Chen SM et al. Comparative analysis of clinical efficacy and drug safety of domestic imatinib and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia in the chronic phase. J. Clin. Hematol. 30(4), 527–531 (2017).
29.
Jiang H, Zhi LT, Hou M, Wang JX, Wu DP, Huang XJ. Comparison of the efficacy and safety of domestic and original imatinib in the treatment of newly diagnosed chronic myelogenous leukemia. Chin. J. Hematol. 38(07), 566–571 (2017).
30.
Tan L, Xie Y, Yang J, Liu L. Curative efficacy of first generation TKI in the treatment of CML-CP combined with vPh and analysis of its genetic characteristics. J. Exp. Hematol. 28(04), 1162–1166 (2020).
31.
Zhong JS, Meng FY, Xu D et al. Follow-up observation of imatinib in the treatment of chronic myeloid leukemia in chronic phase. J. Pract. Med. 28(5), 811–813 (2012).
32.
Wang YM. Discussion on the safety and efficacy of imatinib in the treatment of patients with chronic myeloid leukemia. Chin. Pract. Med. 11(22), 129–130 (2016).
33.
Zhou KS, Wang CC, Zhao YZ et al. Long-term efficacy observation of imatinib in the treatment of 135 cases of chronic myeloid leukemia. J. Leuk. Lymphoma 11, 646–650 (2010).
34.
Jin FF, Lai BB, Zhang YY, Xia HF. Comparison of efficacy and drug resistance of tyrosine kinase inhibitors in chronic and advanced stages of chronic myelogenous leukemia. Chin. J. Prev. Control Chronic Dis. 26(2), 146–150 (2018).
35.
Chen YL, Yin H, Chen LF et al. Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 20(2), E43–E49 (2020).
36.
Xu L, Zhu H, Hu J et al. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase. Front. Med. 9, 304–311 (2015).
37.
Wang AH, Zhou L, You JH, Wang L, Li JM, Hu J et al. Clinical analysis of nilotinib in the treatment of chronic myeloid leukemia resistant or intolerant to imatinib. Chin. J. Hematol. (1), 11–15 (2010).
38.
Wei YQ, Zhang X, Chen WW, Cao R, Yin CX, Feng R et al. Long-term follow-up study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia. J. Southern Med. Univ. 32(7), 1000–1003 (2012).
39.
Zu YL, Zhang YL, Zhou J et al. Interferon combined with imatinib in the treatment of chronic myeloid leukemia with mutations in ABL kinase region. Chin. J. Intern. Med. 55(10), 794–796 (2016).
• ABL kinase region mutation is the leading cause of tyrosine kinase inhibitor (TKI) treatment failure that drives the disease burden of chronic myeloid leukemia (CML).
40.
Liu D, Liu Y, Xue M et al. Responses to dasatinib as a second- and third-line tyrosine kinase inhibitor in chronic phase chronic myeloid leukaemia patients. Acta Haematol. 142, 79–86 (2019).
• ABL kinase region mutation is the leading cause of TKI treatment failure that drives the disease burden of CML.
41.
Xu JJ, Du X, Lou J et al. Clinical analysis of nilotinib in the treatment of imatinib-resistant chronic myeloid leukemia. J. Clin. Hematol. 4, 458–461 (2013).
• ABL kinase region mutation is the leading cause of TKI treatment failure that drives the disease burden of CML.
42.
Pan LQ, Liu WX, Zhu Y et al. Clinical study of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia patients. J. Exp. Hematol. 22(6), 1545–1549 (2014).
• ABL kinase region mutation is the leading cause of TKI treatment failure that drives the disease burden of CML.
43.
Jiang H, Chen SS, Jiang B et al. To evaluate the effect of baseline ABL kinase region point mutations on the efficacy of nilotinib in the treatment of imatinib-resistant or intolerant chronic myeloid leukemia. Chin. J. Hematol. 33(2), 123–126 (2012).
• ABL kinase region mutation is the leading cause of TKI treatment failure that drives the disease burden of CML.
44.
Zhang D, Zhu HL. Clinical outcome and influencing factors of patients with chronic myelogenous leukemia in the chronic phase receiving tyrosine kinase inhibitor treatment and clinical analysis. Int. J. Blood Transfus. Hematol. 42(2), 127–133 (2019).
45.
Qin Y, Chen S, Jiang B et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann. Hematol. 90, 47–52 (2011).
46.
Jing Y, Yang L, Liu DH. Efficacy of TKI in the treatment of chronic myeloid leukemia and related influencing factors analysis of deep molecular response. J. Exp. Hematol. 25(6), 1597–1604 (2017).
47.
Ren WR, Lu SJ, Ren NN, Li XL, Zhu HL. Analysis of the efficacy and safety of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia in the elderly in chronic phase. Int. J. Blood Transfus. Hematol. 39, 471–475 (2016).
48.
Jiang Q, Hu J, Zheng F et al. Baseline characteristics and early monitoring of Chinese CML patients treated with dasatinib: report from a multicenter, observational registry-based study. Blood 128(22), 5439 (2016).
49.
Qiao JH, Zhang ZC, Yao B et al. Efficacy of switching to second-generation tyrosine kinase inhibitors in chronic myeloid leukemia patients with poor response to imatinib. J. Exp. Hematol. 23(1), 65–69 (2015).
50.
Yuan T, Lai YY, Qin YQ et al. Analysis of the efficacy and influencing factors of nilotinib and dasatinib as second and third-line drugs in the treatment of chronic myelogenous leukemia patients in the chronic and accelerated phases. Chin. J. Hematol. 41(2), 93 (2020).
51.
Lu L, Qiao C, Hong M et al. Mean erythrocyte volume can be used as a predictor of the efficacy of chronic myeloid leukemia. J. Exp. Hematol. 26(2), 382–388 (2018).
52.
Shi DY, Qin YQ, Lai YY, Shi HX, Huang XJ, Jiang Q. Distribution of BCR-ABL kinase region mutations in patients with tyrosine kinase inhibitor-resistant chronic myeloid leukemia and its influencing factors. Chin. J. Hematol. 41, 469–476 (2020).
53.
Chen C, Liao LB, Xu D et al. Clinical characteristics of T315I gene mutation in chronic myeloid leukemia and the efficacy of ponatinib. J. Southern Med. Univ. 39(3), 364 (2019).
54.
Lu SJ, Zhu HL, Li XL et al. Clinical efficacy analysis of second-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. J. Sichuan Univ. (Med. Sci.) 47, 287–291 (2016).
55.
Chen YL, Wang L, Yuan GL et al. Efficacy and safety analysis of domestic dasatinib in the second-line treatment of chronic myelogenous leukemia patients. Chin. J. Hematol. 40(2), 98 (2019).
56.
Yu L, Qin YQ, Lai YY et al. A comparative study of nilotinib and imatinib in the first-line treatment of patients with newly diagnosed chronic myelogenous leukemia. Chin. J. Hematol. 40(12), 996 (2019).
57.
Chen DY, Wang J, Zhang LD, Cheng Y, Zhang HB. Analysis of related factors of point mutations in ABL kinase region in patients with TKI-resistant chronic myeloid leukemia. J. Modern Med. Health 37, 569–571 (2021).
58.
Chen LF, Yuan GL, Zhong ZD et al. Efficacy and safety of generic dasatinib as a second-line treatment for patients with chronic myeloid leukemia: a multicenter retrospective study in Hubei province, China. Curr. Med. Sci. 38, 1005–1011 (2018).
59.
Wu LL, Zeng QS, Yang MZ et al. Detection of ABL kinase region point mutations in patients with chronic myeloid leukemia after imatinib treatment. J. Exp. Hematol. 1, 49–53 (2010).
60.
Li XL, Zhu HL, Liu HY et al. Clinical efficacy analysis of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. J. Sichuan Univ. (Med. Sci.) 45, 647–651 (2014).
61.
Wang J, Zhang YL, Zu YL et al. Comparison of the characteristics and efficacy of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia with T315I mutation. Chin. J. Hematol. 37(2), 110 (2016).
62.
Zhang F. Study on the efficacy of imatinib in the treatment of chronic myelogenous leukemia. Med. Community 9, 1 (2020).
63.
Chen YK, Zhang Y, Liu QF et al. Long-term survival analysis of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. J. Intern. Med. Concepts Pract. 1, 5 (2010).
64.
Chen K, He YY. The morphological characteristics and prognosis of bone marrow cells in chronic myelogenous leukemia with acute granulosis and acute lymphoblastic change. Chin. J. Clin. Res. 30(8), 3 (2017).
65.
Chen H, Jiang YQ, Shen YF et al. A clinical study on second-generation tyrosine kinase inhibitors as first-and second-line treatments in chronic myeloid leukemia. Chin. J. Biomed. Eng. 23(6), 479–483 (2017).
66.
Dai LX, Tu XQ, Cai BB. Clinical study of dasatinib in the treatment of patients with chronic myeloid leukemia in different clinical stages. J. Chin. Oncol. 24(10), 997–1001 (2018).
67.
Zhang C. CHG pre-excitation regimen combined with imatinib mesylate in the treatment of acute myeloid transformation of chronic myeloid leukemia. J. Chin. Pract. Diagn. Ther. 28(4), 409–410 (2014).
68.
Pan CY, Li YJ, Li MX et al. Treatment overview and medication compliance analysis of 140 patients with chronic myeloid leukemia. Chongqing Med. 48, 2014–2017 (2019).
69.
Jiang Q, Xu LP, Liu DH et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 117, 3032–3040 (2011).
70.
Xu XH, Xu Y, Ouyang YJ et al. Efficacy of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Jiangsu Med. J. 38, 2405–2407 (2012).
71.
Zhang Y, Chen YK, Fan ZP et al. Analysis of the effect of HLA matching on chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation. J. Southern Med. Univ. 31(3), 438–442 (2011).
72.
Zhang X, Chen XH, Gao L et al. Clinical observation of 52 cases of acute and chronic leukemia treated with allogeneic peripheral blood stem cell transplantation. J. Clin. Hematol. 21(5), 458–460 (2008).
73.
Xia LH, Fang J, Liu F et al. Analysis of curative effect of related allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in 30 cases. Chin. J. Organ Transplant. 28(1), 55–56 (2007).
74.
Wang XB, Liu HL, Geng LQ et al. Allogeneic hematopoietic stem cell transplantation from HLA-contracted donors for treatment of 40 cases of chronic myeloid leukemia. Chin. J. Tissue Eng. Res. 13, 2618–2622 (2009).
75.
Li MX, Wang JS, Zhang Y, Sun ZQ, Zhao P, Lu YH. Clinical observation of imatinib combined with stem cell transplantation in the treatment of chronic myeloid leukemia. Chongqing Med. 42(29), 3554–3556 (2013).
76.
Song AX, Yang DL, Wei JL et al. Preliminary analysis of the efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myeloid leukemia. J. Exp. Hematol. 19, 149–153 (2011).
77.
Zhang LL, Liu HL, Geng LQ et al. Treatment of advanced chronic myeloid leukemia with non-blood cord blood transplantation. J. Leuk. Lymphoma 21(6), 349–352 (2012).
78.
Zhao YL, Zhang JP, Ji SQ et al. HLA haploidentical hematopoietic stem cell transplantation for treatment of advanced chronic myeloid leukemia. Chin. J. Organ Transplant. 33(2), 73–76 (2012).
79.
Zhou M, Sha XS, Qiu HY et al. Retrospective analysis of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Chin. J. Hematol. 35, 126–128 (2014).
80.
Feng SQ, Liu ZB, Yao YH et al. Effect of stratified intervention therapy after allogeneic hematopoietic stem cell transplantation in chronic myelogenous leukemia. J. Clin. Hematol. 31(1), 44–48 (2018).
81.
Li F, Zhang XJ, Zhang RY et al. Imatinib first-line treatment of chronic myeloid leukemia patients in chronic phase-a single-center retrospective analysis. Chin. J. Clin. Oncol. 43, 432–437 (2016).
82.
Wang XB, Sun ZM, Liu HL et al. Efficacy observation and cost analysis of HLA-contracted allogeneic hematopoietic stem cell transplantation for the first chronic phase of chronic myeloid leukemia. J. Clin. Intern. Med. 26(4), 257–260 (2009).
83.
Wang WQ, Bai QX, Chen XQ et al. The efficacy and quality of life follow-up of 34 patients with chronic myeloid leukemia allogeneic hematopoietic stem cell transplantation. Chin. J. Tissue Eng. Res. 11, 9268–9271 (2007).
84.
Zou J, Li WM, Xia LH et al. Differences in efficacy and safety of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia in chronic phase. Chin. J. Tissue Eng. Res. 12, 10184–10188 (2008).
85.
Zhu KE, Xu Y, Zhong J, Chen ST, Zeng HL. BU-CTX2 pretreatment regimen for the treatment of 60 cases of leukemia with allogeneic hematopoietic stem cell transplantation. Chin. J. Hematol. 23, 349–352 (2002).
86.
Xue J, Wang YG, Huang H, Lin MF. Detection of minimal residual disease after unrelated allogeneic bone marrow transplantation in chronic myeloid leukemia by RT-nest-PCR method. J. Clin. Hematol. 20(2), 93–95 (2007).
87.
Xu LP, Guo NL, Huang XJ et al. Effect of interferon alpha on the prognosis of allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Chin. J. Hematol. 22(11), 589–591 (2001).
88.
Xu MZ, Sun AN, Wu DP et al. Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. Shandong Med. J. 51(49), 88–90 (2011).
89.
Wang JM, Zhang WP, Chen L et al. Standard dose and reduced dose preconditioning peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia clinical research. Chin. J. Pract. Intern. Med. S1, 20 (2007).
90.
Tong XZ, Li J, Tan EX et al. Efficacy and prognostic factors analysis of allogeneic hematopoietic stem cell transplantation from HLA-contracted donors in the treatment of chronic myeloid leukemia. Chin. J. Clin. Oncol. 28, 545–548 (2006).
91.
Song XM, Wang JM, Ju XP et al. Clinical study of allogeneic peripheral blood stem cell transplantation in the treatment of chronic myeloid leukemia. Med. J. Chin. People’s Liberation Army 26, 295–297 (2001).
92.
Qian SX, Wu HX, Hong M et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Chin. J. Organ Transplant. 5, 309–310 (2009).
93.
Liu QF, Fan ZP, Sun J et al. Analysis of curative effect of hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia. J. Southern Med. Univ. 24(11), 1227–1229 (2004).
94.
Li WM, Xia LH, You Y, Liu XY, Zhong ZD, Zou P. A clinical comparative study of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of chronic myeloid leukemia. J. Clin. Hematol. 20, 216–219 (2007).
95.
Huang L, Huang H, Cai Z et al. Effect of interferon alpha before transplantation on the prognosis of unrelated allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Zhejiang Med. J. 28(8), 607–609 (2006).
96.
He Y, Feng SZ, Wang M et al. HLA-related allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the first chronic phase of 51 cases. Chin. J. Hematol. 26(7), 389–392 (2005).
97.
Gao XD, Wu W, Zhao WL, Tang W, Shen ZX, Hu J. The clinical significance of BCR-ABL fusion gene detection and pretreatment in patients with chronic myeloid leukemia before and after transplantation. J. Diagn. Concepts Pract. 6(4), 374–375 (2007).
98.
Ding JH, Ma Y, Chen BA et al. Nonmyeloablative peripheral blood stem cell transplantation for chronic myeloid leukemia in chronic and accelerated phases. J. Exp. Hematol. 16, 373–376 (2008).
99.
Cai X, Wei J, He Y et al. A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Int. J. Clin. Pharm. 37, 44–52 (2014).
100.
Gao GL, Xu N, Zhou X et al. Efficacy analysis of imatinib mesylate and allogeneic hematopoietic stem cell transplantation in the chronic phase of chronic myeloid leukemia. Natl Med. J. China 93, 3035–3039 (2013).
101.
Xu L, Xu Z, Zhang X, Chen H, Chen Y, Huang X. Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia. Bone Marrow Transplant. 51, S158–S159 (2016).
102.
Liu QF, Xu XJ, Chen YK et al. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann. Hematol. 90, 331–341 (2011).
103.
Li WM, Xia LH, You Y, Liu XY, Zhong ZD, Zou P. Comparison of the effects of related allogeneic hematopoietic stem cell transplantation and STI571 in the treatment of non-chronic stage chronic myeloid leukemia. Chin. J. Tissue Eng. Res. 11(24), 4742–4746 (2007).
104.
Lu YJ, Sun ZM, Liu HL et al. Allogeneic hematopoietic stem cell transplantation in the treatment of advanced chronic myelogenous leukemia – efficacy analysis of transplantation of non-blood cord blood and sibling donors. Chin. J. Hematol. 35(3), 253–255 (2014).
105.
Shu M, Sun Y, Wang XD. Investigation of health-related quality of life in patients with chronic myeloid leukemia in the chronic phase. J. Modern Med. Health 36, 203–206 (2020).
106.
Goswami P, Ionova T, Oliva EN et al. Final development of the first generic quality of life and symptoms measure specific for hematological malignancies: the HM-PRO. Blood 134, 3484–3484 (2019).
107.
Wang YL, Chen FJ, Luo YQ, Leng YM, Zhu HL. The Chinese version of FACT-Leu scale is used to assess the quality of life of CML patients and analysis of influencing factors. J. Chengdu Med. Coll. 14, 234–239 (2019).
108.
Kantarjian HM, Mamolo CM, Gambacorti-Passerini C et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 124(3), 587–595 (2018).
109.
Huang CF, Shen LJ, Liu YH. Analysis of the budgetary impact of the inclusion of nilotinib in medical insurance for the treatment of imatinib-resistant or intolerant myeloid leukemia patients. Chin. Health Econ. 37(11), 59–63 (2018).
110.
Li N, Zheng B, Cai HF et al. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China. Clin. Drug Invest. 38, 79–86 (2018).
111.
Wang JX, Huang XJ, Wu DP et al. Investigation and analysis of the incidence of chronic myeloid leukemia and current diagnosis and treatment models in 15 hospitals in China. Chin. J. Hematol. 30, 721–725 (2009).
112.
Tang M, He J, Chen M et al. “4+ 7” city drug volume-based purchasing and using pilot program in China and its impact. Drug Discoveries & Therapeutics 13(6), 365–9 (2019).
113.
Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12), 3123–3127 (2012).
114.
Arias E. United States Life Tables, 2006. Natl Vital Stat. Rep. 58(21), 1–40 (2010).
115.
Yang X, Bai Y, Shi M et al. Validation of the EUTOS long-term survival score in Chinese chronic myeloid leukemia patients treated with imatinib: a multicenter real-world study. Cancer Manag. Res. 12, 1293–1301 (2020).
116.
Mori S, Vagge E, Le Courted P et al. Age and d PCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am. J. Hematol. 90(10), 910–914 (2015).
117.
Xia L, Qian W, Yang M, Li Q, Liu F, Xie Y. Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy. Onco Targets Ther. 8, 2485–2492 (2015).
118.
Kantarjian HM, Shah NP, Cortes JE et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119(5), 1123–1129 (2012).
119.
Hochhaus A, O’Brien S, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054–1061 (2009).
120.
Patel AB, O’Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol. Oncol. Clin. North Am. 31(4), 589–612 (2017).
121.
Mealing S, Barcena L, Hawkins N et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis. Exp. Hematol. Oncol. 2(1), 1–9 (2013).
122.
Leong D, Aghel N, Hillis C et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. Heart 107(8), 667–673 (2021).
123.
Wang Z, Jiang L, Yan H, Xu Z, Luo P. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Review of Clinical Pharmacology 14(4), 445–56 (2021).
124.
Oyekunle A, Klyuchnikov E, Ocheni S et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematologica 126(1), 30–9 (2011).
125.
Cortes J, Kim DW, Pinilla-Ibarz J et al. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. Haematologica 100(Suppl. 1), 64 (2015).
126.
Nicolini FE, Basak GW, Kim DW et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15), 2875–2880 (2017).
127.
Gainor JF, Chabner BA. Ponatinib: accelerated disapproval. The Oncologist. 20(8), 847 (2015).
128.
Sharma A, Burridge PW, McKeithan WL et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human pluripotent stem cells. Sci. Transl. Med. 9(377), 2584 (2017).
129.
Singh AP, Glennon MS, Umbarkar P et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc. Res. 115(5), 966–977 (2019).
130.
Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib. Int. J. Cardiol. 316, 214–221 (2020).
131.
Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur. Rev. Med. Pharmacol. Sci. 25(24), 7787–7798 (2021).
Information & Authors
Information
Published In
Pages: 621 - 637
PubMed: 35411807
Copyright
© 2022 Future Medicine Ltd.
History
Received: 15 February 2022
Accepted: 25 March 2022
Published online: 12 April 2022
Keywords:
Topics
Authors
Funding Information
Ascentage Pharma Group Corp Ltd. (Hong Kong)
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2022-0032
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Zhenglei Shen, Honghua Cao, Yeying Zhou, Wenwen Mao, Kunmei Liu, Jingying Zhu, Ming He, Yunru Mao, Ni Luo, Lei Feng, Heng Le, Liying Song, HuaXian Li, Yasar Mehmood Yousafzai, Asad Zia, Xuezhong Gu, Shiwen Zhang, Exosome and BCR-ABL mediated molecular alterations in endothelial cells in chronic myeloid leukemia: identification of seven genes and their regulatory network, PeerJ, 10.7717/peerj.20371, 13, (e20371), (2025).
- Carol Yuk Man Cheung, Chung Yin Ha, Bonnie Kho, Chi Kuen Lau, June Sze Man Lau, Shek Ying Lin, Vivien Wai Man Mak, Raymond Siu Ming Wong, Yok Lam Kwong, Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation, Annals of Hematology, 10.1007/s00277-025-06416-9, 104, 6, (3091-3101), (2025).
- Zilin Li, Yiling Xi, Linglan Tu, Xu Zhang, Yue Huang, Huizong Nie, Cheng Peng, Haohuan Chai, Shenxin Zeng, Xiaoliang Zheng, Liyan Cheng, Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2024.116315, 173, (116315), (2024).
- Romeo G. Mihăilă, Advances in the Treatment of Chronic Myeloid Leukemia, Recent Patents on Anti-Cancer Drug Discovery, 10.2174/1574892818666230111115040, 19, 1, (1-17), (2024).